Who Qualifies for SPRAVATO?
Watch: Who Qualifies for SPRAVATO: The Approved Indications and the Screening Behind Them

From the TMS Therapy Centers Colorado video series. Educational only; not medical advice.
Esketamine has two specific FDA-approved indications, which makes who qualifies for SPRAVATO a narrower question than who might benefit from it. An evaluation works through both. This article explains the criteria, the safety screening, and the practical requirements. It comes from TMS Therapy Centers Colorado, a physician-led psychiatric clinic serving the Denver metro and all of Colorado.
Indication one: treatment-resistant depression
The first indication is treatment-resistant depression in adults. In practical terms, that generally means a diagnosis of major depressive disorder and an inadequate response to at least two different antidepressants, each taken at an adequate dose for an adequate length of time during the current episode.
Records of past medications, doses, and durations are therefore useful at the evaluation. If you do not have exact records, pharmacy histories and prescriber notes can often fill in the gaps. Our treatment-resistant depression page explains the term in more detail.
Indication two: suicidal thoughts or actions
The second indication is major depressive disorder with acute suicidal thoughts or actions in adults, where SPRAVATO is given together with an oral antidepressant as part of a broader plan of care.
If you are in crisis, call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room.
Conditions that make esketamine a poor idea
Beyond the indications, the evaluation checks for conditions that make esketamine a poor idea:
- Aneurysmal vascular disease
- A history of bleeding in the brain
- Uncontrolled high blood pressure
- A few others
The reason is the temporary rise in blood pressure it can cause. Pregnancy and breastfeeding are generally reasons to choose a different route.
Factors weighed carefully
A history of psychosis, certain substance use patterns, and some medication combinations are weighed carefully rather than treated as automatic exclusions. That means they lead to a conversation, not an automatic refusal. A psychiatrist considers how the factor interacts with treatment and whether it can be managed safely.
Practical qualifications
The person also needs to attend supervised sessions in person and arrange a ride home each time. That is a practical qualification as much as a medical one. Without reliable rides and the ability to attend, treatment is difficult to carry out safely. We cover the ride requirement in our article on driving after SPRAVATO.
Adults only
The approvals cover adults, so SPRAVATO is not an option for teenagers. Families looking for help for a teenager can ask about other options at an evaluation.
You do not need to have run out of options
The criteria do not require that a person has run out of every other option. Many people who qualify are also candidates for TMS or for off-label ketamine therapy, and choosing among them is part of what the evaluation is for. TMS is FDA-cleared for major depressive disorder, and ketamine for depression is off-label. You can compare approaches on our SPRAVATO vs TMS article.
Why the criteria are framed this way
The indications reflect what the clinical studies behind the approvals actually tested. Treatment-resistant depression is defined by inadequate response to prior treatment because that is the group in which esketamine was studied and approved. The second indication exists because standard antidepressants usually need several weeks, and there is a particular need for options when depression comes with acute suicidal thoughts or actions. Understanding that logic helps explain why an evaluation asks so many questions about past medications and current safety.
Qualifying is a clinical decision, not a form
Meeting the indication on paper is only part of the picture. A psychiatrist also weighs how severe the depression is, how past treatments went, what side effects were experienced, medical history, and what the person wants. Two people who both meet the criteria may be steered toward different options. One may be better suited to SPRAVATO and another to TMS, and some may be good candidates for more than one. The evaluation is where those judgments are made carefully rather than by checklist.
What if you do not qualify
Not qualifying for SPRAVATO does not mean there is nothing to try. Depression that has not responded to medication has other options, including TMS therapy, which is FDA-cleared for major depressive disorder. A psychiatrist can explain which options fit your history and why.
What to bring
A few items make an evaluation more productive:
- A list of antidepressants you have tried, with doses and dates if possible
- A list of current medications and supplements
- Any history of high blood pressure, vascular conditions, or bleeding in the brain
- A note on alcohol and other substance use
- Your ride-home plan
What the evaluation covers
The evaluation reviews symptoms and history, applies the criteria above, and checks safety factors. It is also where the question of an oral antidepressant is decided. Since 2025, SPRAVATO is approved on its own as well as with an oral antidepressant for treatment-resistant depression in adults; the second indication still requires the oral antidepressant. A review of current medications is part of that conversation.
How care works at TMS Therapy Centers Colorado
TMS Therapy Centers Colorado was founded by William Kromka, MD, a board-certified psychiatrist. The evaluation can take place in person or by private video anywhere in Colorado, no referral is needed, and benefits are verified before treatment begins. Most major insurance plans are accepted, and prior authorization is handled before treatment starts. To begin, call 720-500-7873.